ClinicalTrials.gg
RecruitingNCT06757504Updated May 14, 2025

Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD

A Phase 2 interventional study of TTYP01 Tablets (12mg or 18mg) and Placebo (Simulant TTYP01 Tablets) in Autism Spectrum Disorder (ASD), sponsored by Shanghai Auzone Biological Technology Co., Ltd.. Recruiting at 5 sites in China. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Shanghai Auzone Biological Technology Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
6 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Autism Spectrum Disorder with a site in China — 37 open to participants now, 38 under way, none of them phase 3. Autism Spectrum Disorder · China.

Planned enrollment
16th of 63
150 · median 96
Started
2025
with 18 others
Phase 2
7 of 86
2 open now
Primary completion
2026-02
later than 11 of 37 live
Registered
50th of 86
by date

Among the 86 studies in Autism Spectrum Disorder with a site in China, this one is the 16th largest by planned enrollment of the 63 interventional ones that give a count, is one of 19 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 11 of the 37 other live ones, and was the 50th registered.

Autism Spectrum Disorder

1,728 studies on the registry are indexed under Autism Spectrum Disorder; 501 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

37 of the 86 studies in Autism Spectrum Disorder with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.

This study: 6 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Autism Spectrum Disorder with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.

Read the detailed description

This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.

The trial will be conducted in 3 stages. It plans to firstly enroll 24 adolescent participants (≥12 to \< 16 years) with ASD. After all the 24 adolescent participants have completed the 4-week follow-up and observation, the Data and Safety Monitoring Board (DSMB) will review the data obtained from these adolescent participants, and then make a recommendation on whether to enroll pediatric participants (≥6 to \< 12 years) with ASD and continue the adolescent participants' enrollment, whether it is necessary to adjust the protocol, or whether to terminate the trial for safety considerations, etc. If pediatric participants can be enrolled, it plans to first enroll 24 pediatric participants, and the DSMB will review all data after all these participants have completed the 4-week follow-up and observation, and then make a recommendation on whether to continue enrollment of adolescent and pediatric participants, whether to adjust the protocol, or whether to terminate the trial for safety considerations, etc. If the enrollment of adolescent and pediatric participants can be continued, the trial will proceed to Stage 3 until 150 adolescent and pediatric participants with ASD are enrolled. In addition, throughout the trial, the DSMB may conduct irregular reviews of safety, tolerability, PK, and efficacy data, and give recommendations based on the results of the review, including but not limited to adjusting the trial protocol and early termination of the trial for safety considerations. A DSMB review is triggered if a neurotoxicity AE occurs. The composition, responsibilities, etc. of the DSMB are described in Section 4.2 of the protocol.

Eligible participants will be randomized in a 1:1:1 ratio to receive TTYP01 low-dose, TTYP01 high-dose and placebo treatment. Randomization is stratified by age group (≥12 vs \< 12 years of age). Participants will be given the corresponding dose of the investigational product for 12 weeks based on their weight and groups as listed in the table in the protocol. The dosing regimen can be adjusted based on the safety, tolerability, PK and other data accumulated in the previous period.

03

Conditions studied

  • Autism Spectrum Disorder (ASD)
04

Who can participate

Ages eligible
6 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible for the study only if all of the following inclusion criteria are met:

  1. Aged ≥ 6 to \<16 years at the time of signing the ICF (age \<16 years after 12-week treatment), including adolescents aged ≥ 12 to\<16 years at the time of signing the ICF (age \<16 years after 12-week treatment), and children aged ≥ 6 to\<12 years at the time of signing the ICF;
  2. Male or female;
  3. Participants diagnosed with ASD according to the ASD diagnostic criteria in , Fifth Edition (DSM-5) and confirmed by the Schedule for Affective Disorders and Schizophrenia for School Aged Children Present and Lifetime version (K-SADS-PL), DSM-5 ASD module;
  4. Child Autism Rating Scale 2-ST (CARS 2-ST) raw score ≥36;
  5. CGI-S score ≥4;
  6. Participants and their legal guardians understand and are willing to participate in this trial, with ICF signed by the legal guardian and participants aged ≥ 8 years; for participants who, at the discretion of the investigator, have cognitive deficits that prevent them from signing the ICF, their legal guardians sign the ICF on behalf of them;
  7. Females of (as defined in Appendix 15.1) agree to remain abstinent or use a reliable method of for the duration of the trial and until 3 months after the last dose of the product.

Exclusion criteria

Exclusion Criteria:

Any participant who meets any of the following criteria will be excluded:

  1. Weight \<20.0 kg or >70.0 kg, or ≥35.0 kg/m\^2;
  2. Pregnant or lactating women;
  3. Presence of a serious mental disorder as assessed by the investigator, e.g., schizophrenia, bipolar disorder, depressive disorder, etc.; the presence of significant anxiety, tension, agitation, fear, depression, or the presence of suicidal risk, significant risk of self-injury, impulsivity, aggression, or behaviors based on the medical history and the routine mental status examination;
  4. History of epileptic seizures within 3 months prior to screening, or presence of a history of severe physical or neurological disease, history of severe head trauma;
  5. Participants with a history or symptoms of other mental illness that, at the discretion of the investigator, may affect the results of the study;
  6. Participants with a history of any unstable physical or neurological condition or currently suffering from a physical or neurological condition that, at the discretion of the investigator, may put them at risk of a significant adverse event or interfere with the assessment of safety and efficacy during the course of the trial;
  7. Pre-existing educational training and/or behavioral treatments fail to be stabilized prior to screening and consistent throughout the trial;
  8. Participants who are unable to discontinue or may use other treatments during the screening period and throughout the trial due to their condition, including: antipsychotic medications (except those that may be used in combination during the trial as specified in the protocol), medications that may have a therapeutic effect on ASD, nootropic drugs, medications for ADHD, intestinal flora modification, and other intestinal flora modification supplementation alternatives;
  9. Participants who have used treatment modalities such as transcranial magnetic stimulation therapy, direct current stimulation therapy, electroencephalographic biofeedback therapy, auditory integration training, executive function training, acupuncture therapy, etc., within 2 months prior to randomization, or may use such treatments during the treatment period;
  10. 12- and laboratory results as outlined below: (1) is outside the normal range of the site; (2) are below the lower limit of normal for the site; (3) is below the lower limit of normal for the site; (4) is below the lower limit of normal for the site; (5) or AST ≥ 2 × , or total > upper limit of normal for the site; (6)Urea nitrogen or creatinine is above the upper limit of normal for the site; (7)Any other abnormal laboratory, vital sign, or 12-ECG findings that, at the discretion of the investigator, are abnormal and and will affect the safety of the participant or the interpretation of the study results;
  11. Participation in any clinical trial of a drug or non-drug intervention within the last 1 month;
  12. Concomitant medications/therapies that are prohibited in the protocol may be required during the trial;
  13. Participants expected to undergo elective surgery during the trial;
  14. Participants whose parents/guardians are unable to understand and/or complete the scale assessments in this trial.
  15. to edaravone and (Soluplus, sodium bisulphite, microcrystalline cellulose, magnesium stearate, polyvinylpolypyrrolidone) in TTYP01 tablets;
  16. Participants who are judged by the investigator to be ineligible for other reasons.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    TTYP01 low-dose group

    TTYP01 Tablets (12mg or 18mg), Twice daily for 12 weeks. Dosage is determined based on body weight and group assignment, with the low-dose group receiving 12mg-30mg BID, the dosing regimen is detailed in the trial protocol.

    Drug: TTYP01 Tablets (12mg or 18mg) · Drug: Placebo (Simulant TTYP01 Tablets)

  • Experimental
    TTYP01 high-dose group

    TTYP01 Tablets (12mg or 18mg), Twice daily for 12 weeks. Dosage is determined based on body weight and group assignment, with the high-dose group receiving 24mg-60mg BID, the dosing regimen is detailed in the trial protocol.

    Drug: TTYP01 Tablets (12mg or 18mg) · Drug: Placebo (Simulant TTYP01 Tablets)

  • Placebo comparator
    Placebo group

    Simulant TTYP01 Tablets, Twice daily for 12 weeks.

    Drug: Placebo (Simulant TTYP01 Tablets)

Interventions

  • Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.

  • DrugPlacebo (Simulant TTYP01 Tablets)

    Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.

06

What researchers measure

Primary outcomes

  1. Change from baseline in ABC-SW(Aberrant Behavioral Checklist - Social Withdrawal) scores at Week 12.

    The ABC (Aberrant Behavioral Checklist) scale has 58 items. The scale is broken down into five subscales including ABC-SW(Aberrant Behavioral Checklist - Social Withdrawal), ABC-I, A, C (Aberrant Behavioral Checklist - Irritability, Agitation, Crying), ABC-SB (Aberrant Behavioral Checklist - Stereotypic Behavior), ABC-H, N (Aberrant Behavioral Checklist - Hyperactivity, Noncompliance ), and ABC-IS (Aberrant Behavioral Checklist - Inappropriate Speech ). Scale ratings can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others with knowledge of the person being assessed. The rater has to answer each of the 58 questions using a 4-point Likert scale. A score of a "0" means the behavior is not a problem, a score of a "1" means slight problem, a score of a "2" means a serious problem, and a "3" means a severe problem.

    Time frame: At baseline and week 12

  2. Incidence and severity of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), serious adverse events (SAEs), and TEAEs that lead to treatment discontinuation.

    To evaluate the safety and tolerability of TTYP01 tablets in adolescent and pediatric participants with ASD.

    Time frame: Throughout the trial period

  3. Plasma concentrations and population PK profiles of edaravone and its metabolites in adolescent and pediatric ASD participants.

    Concentrations of edaravone and its metabolites are assayed in the plasma of adolescent and pediatric participants with ASD. They will be analyzed with descriptive statistics according to planned sampling points.

    Time frame: Visit 2 (Day 1): 30 minutes (±5 minutes) and 3 hours (±10 minutes) after the first dose; Visit 8 (Week 12 ±2 Days)or Early withdrawal: before the first dose (0 hour), and 30 minutes (±5 minutes) after the first dose on the day of the visit.

Secondary outcomes

  1. Changes from baseline in ABC-SW scores at Weeks 4 and 8.

    The ABC (Aberrant Behavioral Checklist) scale has 58 items. The scale is broken down into five subscales including ABC-SW(Aberrant Behavioral Checklist - Social Withdrawal), ABC-I, A, C (Aberrant Behavioral Checklist - Irritability, Agitation, Crying), ABC-SB (Aberrant Behavioral Checklist - Stereotypic Behavior), ABC-H, N (Aberrant Behavioral Checklist - Hyperactivity, Noncompliance ), and ABC-IS (Aberrant Behavioral Checklist - Inappropriate Speech ). Scale ratings can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others with knowledge of the person being assessed. The rater has to answer each of the 58 questions using a 4-point Likert scale. A score of a "0" means the behavior is not a problem, a score of a "1" means slight problem, a score of a "2" means a serious problem, and a "3" means a severe problem.

    Time frame: At baseline, Weeks 4 and 8

  2. Changes from baseline in other ABC subscale scores at Weeks 4, 8 and 12.

    The ABC (Aberrant Behavioral Checklist) scale has 58 items. The scale is broken down into five subscales including ABC-SW(Aberrant Behavioral Checklist - Social Withdrawal), ABC-I, A, C (Aberrant Behavioral Checklist - Irritability, Agitation, Crying), ABC-SB (Aberrant Behavioral Checklist - Stereotypic Behavior), ABC-H, N (Aberrant Behavioral Checklist - Hyperactivity, Noncompliance ), and ABC-IS (Aberrant Behavioral Checklist - Inappropriate Speech ). Scale ratings can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others with knowledge of the person being assessed. The rater has to answer each of the 58 questions using a 4-point Likert scale. A score of a "0" means the behavior is not a problem, a score of a "1" means slight problem, a score of a "2" means a serious problem, and a "3" means a severe problem.

    Time frame: At baseline, Weeks 4, 8 and 12

  3. Clinical Global Impressions-Improvement (CGI-I) scores at Weeks 4, 8, and 12.

    The CGI includes the CGI-S and CGI-I. The CGI rating scale allows for an overall assessment of participant improvement over time. At baseline, the CGI-S assessment is performed and the rating investigator rates the severity of the participant's condition based on a 7-point scale ranging from 1 (no symptoms) to 7 (very severe symptoms). At the follow-up visit, the scoring investigator assessed the degree of improvement in the participant's symptoms relative to baseline based on the CGI-I items on a 7-point scale ranging from 1 (very marked improvement) to 7 (very marked deterioration).

    Time frame: At Weeks 4, 8, and 12.

  4. Changes from baseline in Clinical Global Impressions-Severity (CGI-S) scores at Weeks 4, 8, and 12.

    The CGI includes the CGI-S and CGI-I. The CGI rating scale allows for an overall assessment of participant improvement over time. At baseline, the CGI-S assessment is performed and the rating investigator rates the severity of the participant's condition based on a 7-point scale ranging from 1 (no symptoms) to 7 (very severe symptoms). At the follow-up visit, the scoring investigator assessed the degree of improvement in the participant's symptoms relative to baseline based on the CGI-I items on a 7-point scale ranging from 1 (very marked improvement) to 7 (very marked deterioration).

    Time frame: At baseline, Weeks 4, 8 and 12

  5. Changes from baseline in Social Responsiveness Scale 2 (SRS-2) total scores at Weeks 4, 8, and 12.

    The SRS-2 assesses participants' social communication, social awareness, social motivation, and self-regulation. Scales can be completed by parents and teachers.Both the SRS-2 total score and the five subscale scores can be used to assess the severity of ASD symptoms. The SRS-2-School Age was used in this study. The SRS-2 contains 65 items, each of which is rated by the assessor on a scale of 1 (not true), 2 (sometimes true), 3 (often true), and 4 (almost always true) based on the behavioral performance of the person being assessed. Scores range from 65-260, where higher scores indicate more severe social problems.

    Time frame: At baseline, Weeks 4, 8 and 12

  6. Changes from baseline in Autism Treatment Evaluation Checklist (ATEC) total scores at Weeks 4, 8, and 12.

    The ATEC contains four subscales: language/communication, social, sensory/cognitive awareness, and health/physical/behavioral, and scale ratings can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others who know the person being assessed. Scores from each subscale are combined to calculate a total score, which ranges from 0 to 179. Higher scores indicate more severe autism symptoms and behavioral problems, and lower scores indicate improvement in symptoms.

    Time frame: At baseline, Weeks 4, 8 and 12

  7. Changes from baseline in the total score of the Attention-Deficit Hyperactivity Disorder Rating Scale-IV - Home version (ADHD-RS-IV [Home version]) at Weeks 4, 8, and 12.

    The ADHD-RS assesses the child's attention deficit and hyperactive/impulsive behaviors over the past six months. Scale ratings can be completed by parents and teachers. The ADHD-RS consists of 18 items that cover various aspects of attention and hyperactivity symptoms. Participants assess the extent of each item based on their performance using a four-point scale:0 (Never or Rarely), 1 (Sometimes), 2 (Often), and 3 (Very Often). By combining these items, a composite score can be derived that measures the severity of attention deficit and hyperactivity symptoms. Higher scores indicate more severe symptoms.

    Time frame: At baseline, Weeks 4, 8 and 12

  8. Changes from baseline in Behavior Rating Inventory of Executive Function (BRIEF) (Parent Version) scores at Weeks 4, 8, and 12.

    The Children's BRIEF (Parent Version) assesses executive functioning in children and adolescents, including aspects of working memory, planning/organization, and task monitoring, and the scale can be completed by a parent or guardian. The first version of the Children's BRIEF (Parent Version) was used in this study. The parent version of the BRIEF for school-age children assesses the executive functioning of children aged 6 to 18 years old, and contains 86 items divided into 2 latitudes: behavioral regulation index (BRI, including 3 factors of inhibition, switching and emotional control) and metacognition index (MI, including 5 factors of task initiation, working memory, planning, organizing and monitoring). Each item was rated on a scale of 1 to 3 (1=never; 2=sometimes; 3=often), with higher ratings reflecting more severe impairment of executive function.

    Time frame: At baseline, Weeks 4, 8 and 12

  9. Proportion of participants with ≥25% reduction in ABC-SW score relative to baseline at Week 12.

    The ABC (Aberrant Behavioral Checklist) scale has 58 items. The scale is broken down into five subscales including ABC-SW(Aberrant Behavioral Checklist - Social Withdrawal), ABC-I, A, C (Aberrant Behavioral Checklist - Irritability, Agitation, Crying), ABC-SB (Aberrant Behavioral Checklist - Stereotypic Behavior), ABC-H, N (Aberrant Behavioral Checklist - Hyperactivity, Noncompliance ), and ABC-IS (Aberrant Behavioral Checklist - Inappropriate Speech ). Scale ratings can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others with knowledge of the person being assessed. The rater has to answer each of the 58 questions using a 4-point Likert scale. A score of a "0" means the behavior is not a problem, a score of a "1" means slight problem, a score of a "2" means a serious problem, and a "3" means a severe problem.

    Time frame: At baseline and week 12

  10. Proportion of participants with a CGI-I score ≤ 2 at Week 12.

    The CGI includes the CGI-S and CGI-I. The CGI rating scale allows for an overall assessment of participant improvement over time. At baseline, the CGI-S assessment is performed and the rating investigator rates the severity of the participant's condition based on a 7-point scale ranging from 1 (no symptoms) to 7 (very severe symptoms). At the follow-up visit, the scoring investigator assessed the degree of improvement in the participant's symptoms relative to baseline based on the CGI-I items on a 7-point scale ranging from 1 (very marked improvement) to 7 (very marked deterioration).

    Time frame: At Week 12

Other outcomes

  1. Changes from baseline in the proportion of time spent looking at different facial areas and social situations in eye-tracking tasks by eye-tracking method at Week 12 of administration.

    Exploratory objective metrics that may predict benefit from TTYP01 tablets

    Time frame: At baseline and week 12

  2. Changes from baseline in fNIRS examination at Week 12.

    Exploratory Outcomes, Objectivity indicators that may predict benefit from TTYP01 tablets

    Time frame: At baseline and week 12

  3. Changes from baseline in the level of plasma cytokines (i.e., IL-1β, IL-6, TNF-α, INF-γ, IL-7, IL-12, and IL-17) at Week 12.

    Exploratory Outcomes, Biomarker indicators that may predict benefit from TTYP01 tablets

    Time frame: At baseline and week 12

  4. Changes from baseline in the levels of plasma reduced glutathione (GSH), oxidized glutathione (GSSG), and GSH/GSSG at Week 12.

    Exploratory Outcomes, Biomarker indicators that may predict benefit from TTYP01 tablets

    Time frame: At baseline and week 12

  5. Changes from baseline in Total Antioxidant Capacity (T-AOC) of urine at Week 12.

    Exploratory Outcomes, Biomarker indicators that may predict benefit from TTYP01 tablets

    Time frame: At baseline and week 12

07

Study locations

1 of 5 sites recruiting
  • Peking University Sixth Hospital
    Beijing, China
    Recruiting
    • Jing Liu · Contact
  • The Second Xiangya Hospital of Central South University
    Changsha, China
    Not yet recruiting
    • Xuerong Luo · Contact
  • West China Hospital of Sichuan University
    Chengdu, China
    Not yet recruiting
    • Yi Huang · Contact
  • Nanjing Brain Hospital, The Affiliated Brain Hospital of Nanjing Medical University
    Nanjing, China
    Not yet recruiting
    • Xiaoyan Ke · Contact
  • Tianjin Mental Health Center
    Tianjin, China
    Not yet recruiting
    • Ling Sun · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2026, 12 months after the start.

Of 82 phase 2 interventional studies under Autism Spectrum Disorder, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 52. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2024
First posted
Jan 3, 2025
StartActual
Jan 13, 2025
Primary completionEst.
Feb 6, 2026
CompletionEst.
May 8, 2026
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06757504
Lead sponsor
Shanghai Auzone Biological Technology Co., Ltd.
Responsible party
Sponsor
First posted
Jan 3, 2025
Start date
Jan 13, 2025
Primary completion
Feb 6, 2026 (estimated)
Completion
May 8, 2026 (estimated)
Last update
May 14, 2025

Study contacts

Xiaolong Hou
Contact
houxl@auzonebio.com
+86-21-65039008
Jing Liu
study chair · Peking University Sixth Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TTYP01

Start the discussion